相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
1
50.0%
Unknown
1
50.0%
暂无批准数据
- The LatAm-FINGERS trial, spanning 11 Latin American countries, demonstrated that a culturally adapted multidomain lifestyle intervention can be successfully implemented across diverse communities and deliver cognitive benefits. - Participants receiving the structured Systematic Lifestyle Intervention improved overall cognition 55% more than those in the flexible guidance group after two years. - The structured group also showed significantly larger gains in memory, executive function, and processing speed, underscoring that structure and social support matter. - The findings extend U.S. POINTER evidence and suggest the intervention model can be adapted for diverse populations worldwide, potentially combined with emerging drug therapies.
- The U.S. Preventive Services Task Force has been blocked from meeting since March 2025, stalling new guidance on cognitive decline screening despite the health secretary's calls for action. - Health Secretary Robert F. Kennedy Jr. has called the lack of early Alzheimer's screening "regulatory malpractice," yet his department dismissed the task force's leadership and failed to fill vacancies. - An estimated 7.4 million Americans aged 65 and older live with Alzheimer's disease, and researchers say science has been "slowed down" by funding disruptions affecting 14 of 35 Alzheimer's Disease Research Centers. - Experts caution that emerging blood biomarker tests like P-Tau217 have diagnostic but not prognostic value, and widespread screening rollout remains scientifically contentious.
- Blood-based biomarker tests for Alzheimer's are emerging as accessible alternatives to brain scans and spinal taps, with potential for use in primary care settings. - The Alzheimer's Association has begun issuing clinical guidelines for physicians on how to use these blood-based diagnostic tools. - Experts emphasize that earlier diagnosis is critical given the availability of new Alzheimer's treatments that are more effective when used early in the disease course. - Specialist wait times for neurologists can extend for months or over a year, making primary care-based testing a crucial pathway for timely diagnosis.
- Women account for nearly two-thirds of Alzheimer's diagnoses and provide the majority of unpaid dementia care, yet their brain health remains under-studied and underprioritized in research. - The WHO estimates dementia costs the global economy $1.3 trillion currently, projected to rise to $2.8 trillion by 2030, with roughly half attributed to informal caregiving. - Three leading organizations—Alzheimer's Research UK, the Alzheimer's Association, and the Women's Alzheimer's Movement at Cleveland Clinic—issued a joint call for urgent investment in sex-specific research, representative clinical trials, and policy reform. - The coalition demands governments renew commitment to the WHO global dementia plan, ensure every country adopts a national action plan by 2031, and formally recognize unpaid caregiving as labor.
- The Alzheimer's Association Brain Health Summit in Hawaii highlighted new disease-modifying treatments, blood biomarker testing, and the importance of early detection for Alzheimer's disease. - Hawaii passed landmark legislation requiring cognitive screening during Medicare annual wellness visits and established the HANAI Memory Network Program to support dementia care. - Over 100,000 Hawaii residents are affected by Alzheimer's, and the state has the fifth fastest-growing Alzheimer's mortality rate nationwide. - The U.S. POINTER study demonstrated that combining physical activity, cognitive exercise, and a brain-healthy diet can improve cognition in older adults.
- Patient advocates and medical experts are urging Oregon lawmakers to pass legislation in 2027 requiring health insurers to cover FDA-approved biomarker testing. - Biomarker tests can detect diseases like Alzheimer's and cancer through tissue, blood, or fluid samples, enabling personalized and targeted treatment strategies. - Nearly half of U.S. states already mandate biomarker test coverage, and Oregon advocates argue the state should join them to improve patient outcomes. - Personal testimonies from an Alzheimer's patient and an OHSU oncologist highlight how biomarker testing led to accurate diagnoses and effective targeted therapies.
- A study of over 17,000 adults found that several modifiable dementia risk factors have a disproportionately larger impact on cognitive decline in women compared to men. - Cardiovascular and metabolic conditions, including hypertension and higher BMI, showed stronger negative associations with cognitive function in women, despite some being more prevalent in men. - Women were nearly twice as likely to report depression (17% vs. 9%) and had higher rates of physical inactivity and sleep problems, while men had higher rates of hearing loss and diabetes. - Researchers advocate for sex-specific prevention strategies, emphasizing that tailoring interventions to how strongly risk factors affect each sex could reduce dementia burden, especially for women.
- NeuroTherapia completed its Phase 2a trial of NTRX-07 in 48 Alzheimer's disease patients, meeting primary safety and tolerability objectives with no treatment-related serious adverse events. - The 28-day double-masked, randomized trial demonstrated positive multi-domain signals across safety, pharmacokinetics, biomarkers, MRI, EEG, and clinical outcomes. - Preliminary MRI findings showed directionally supportive changes trending toward stabilization on active treatment, supporting the neuroinflammation hypothesis in AD progression. - NTRX-07 is an oral small molecule targeting receptors involved in neuroinflammation, with preclinical data showing restored microglial function and improved neuronal plasticity.
- ImmunoBrain will present Phase 1b clinical data for IBC-Ab002, a proprietary anti-PD-L1 monoclonal antibody designed for Alzheimer's disease treatment, at the AD/PD 2026 conference in Copenhagen. - The presentation will include safety, tolerability and biomarker data from the first 40 patients who received four intravenous infusions across five escalating dose cohorts in the IBC-01-01 study. - IBC-Ab002 represents a novel approach using immune checkpoint blockade to activate the peripheral immune system for brain protection and repair in neurodegenerative diseases. - The therapy is based on over 25 years of research showing the brain's dependence on immune system viability for protection and repair mechanisms.
- Italian researchers have developed lithium-loaded gold nanoparticles delivered via nasal spray that target the brain directly, bypassing systemic circulation and reducing side effects associated with oral lithium therapy. - The nanotechnology successfully inhibited GSK-3β enzyme activity in mouse hippocampus and restored memory deficits in an Alzheimer's disease model after two months of treatment. - The approach achieves therapeutic lithium concentrations using significantly lower doses than oral administration, potentially revolutionizing treatment for bipolar disorder, Alzheimer's disease, and viral brain infections. - The technology has received patents in Italy and internationally, with ongoing studies to assess safety and expand clinical applications for neuropsychiatric and neurodegenerative diseases.
